Biotech | April 25, 2022
CanSinoBIO rebrands to reflect commitment to life sciences research
This is the first major brand refresh of CanSinoBIO since its inception in 2009
This is the first major brand refresh of CanSinoBIO since its inception in 2009
The proposed life sciences research and development centre in North of England region of UK will support acceleration of the company’s research in the areas of biotechnology, health and life sciences
Continuation of pediatric expansion in adolescents of PREVENT-19 Phase 3 trial will evaluate safety and immunogenicity of a booster dose
Immune response confirmed in stand-alone influenza vaccine and combination vaccine with a potential path forward for both
The life sciences and pharmaceutical sectors suffer from hard-to-source biological materials, which translates into high costs in research and development
The joint partnership, powered by Cloudbyz Clinical Research Management Platform and ClinChoice's industry-leading transformation services, will provide an end-to-end clinical research management technology platform and services to customers
Headwinds related to pricing pressures and rising raw material costs will result in some contraction in margins in Q4 FY22 and FY23
Iktos and Teijin Pharma will collaborate in developing new AI technology aiming to bring further improvement and speed to the drug design process
R&D investment up 11.7% to 4.1 billion EUR in 2021 (20.0% of net sales)
CanSinoBIO will continue to focus on developing a variety of innovative preventive vaccines in its diversified product pipeline with proprietary technologies, including the inhaled version of its COVID-19 vaccine, Convidecia
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
